AdipoGen Life Sciences COVID-19 antiviral research compounds
There are no approved drugs to treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19). Existing drugs, which have a known favourable safety profile, are being examined for strategies to treat the disease and fast-track a treatment plan. Several influenza and HIV drugs are currently undergoing clinical trial in coronavirus patients. The rational selection of drugs already on the market is being made based on their ability to inhibit any proteins essential for virus-receptor interaction and/or viral life cycle.
AdipoGen Life Sciences’ range of Small Molecule SARS-CoV-2 Inhibitors and Modulators offers potential tools for in vitro studies of COVID-19. The company’s product range includes research compounds targeting viral transcription, replication and maturation.
Phone: 02 9698 2022
Bio-Rad Laboratories anti-idiotypic antibodies and Human IgM-FcSpyCatcher reagent
Bio-Rad Laboratories has extended its range of recombinant monoclonal anti-idiotypic antibodies...
ProSci Incorporated apoptosis antibodies
ProSci Incorporated provides an extensive catalogue of apoptotic antibodies including death...
TdB Labs polysaccharides
TdB Labs' polysaccharide portfolio consists of both fluorescent and non-fluorescent...
